Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Overactive bladder is a common urologic disorder with a number of etiologies and evolving treatment options. The two primary management strategies are drug therapy and sacral neurostimulation, both areas of recent developments with the emergence of new medications and refinement of surgical techniques. In this Viewpoint, Apurba Pathak and Sherif Aboseif discuss the relative merits, and drawbacks, of these very different approaches.
Retroperitoneal lymph node dissection (RPLND) is used in both the staging and management of non-seminomatous germ-cell tumors. Although a number of advantages of the laparoscopic approach have been reported over open RPLND, its use has not been supported by formal internal review board-approved studies. Brett Carver and Joel Sheinfeld discuss RPLND in the management of these tumors, both before and after chemotherapy.
In this review, Fiona Burkhard and colleagues discuss the use of retroperitoneal lymph node dissection in both the staging and treatment of prostate cancer. Their discussion covers the preoperative methods used to assess lymph nodes and compares the merits and drawbacks of extended compared to limited lymphadenectomy when staging prostate cancer, and their possible influence on patient survival.
Invasive urologic procedures carry the potential to cause hemorrhaging, the risk of which is greater for patients receiving long-term anticoagulation therapy. Paul Daniels reviews these risks and the management options that can be used to balance the risks of hemorrhage against the problems of venous thromboembolism, if anticoagulation therapy is stopped in this group of patients.
